Antimicrobial Peptides Market Size is valued at USD 223.90 Mn in 2023 and is predicted to reach USD 532.02 Mn by the year 2031 at a 11.65% CAGR during the forecast period for 2024-2031.
AMPs possess the ability to eliminate microbial pathogens directly; others function indirectly by modulating host defense systems. Natural antimicrobial peptides are found in bacterial and eukaryotic defense systems. They defend against bacteria, viruses, and fungi. They target cytoplasmic membranes, cell walls, DNA, and proteins, hence their composition is crucial. Direct-to-Consumer genetic testing is in demand due to better understanding of its benefits, such as tracing ancestry, assessing sickness risks, and delivering personalized healthcare information.
The increased awareness of medications and therapies incorporating antimicrobial peptides is anticipated to enhance the global market for such peptides significantly. Chronic conditions where antibiotic resistance remains ineffectual offer particularly attractive opportunities for antimicrobial peptide manufacturers. Moreover, continual advancements in biotechnology are streamlining the development and production processes of antimicrobial peptides, thereby facilitating market expansion. There is a growing acknowledgment of infection control measures, particularly within healthcare settings, driving the demand for antimicrobial peptides as effective solutions.
Additionally, persistent investments in research and development activities are driving the discovery and innovation of new antimicrobial peptides, thus maintaining market momentum. Additionally, stringent regulatory standards governing the approval process of antimicrobial peptides pose challenges, potentially leading to delays in market entry and increased development costs. Despite promising research findings, not all antimicrobial peptides smoothly transition from experimental stages to viable commercial products, introducing uncertainties regarding their market viability.
Competitive Landscape
Some Major Key Players In The Antimicrobial Peptides Market:
- Novozymes A/S
- Polypeptide Group
- Bachem Holding AG
- Wuxi Apptec
- Ana Spec Inc. (a Eurofins Company)
- Merial
- Ipsen S.A.
- AstraZeneca
- Pfizer Inc.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Sandoz International GmbH
- Polymedia
- Magennis Inc.
- Probiotic Limited
- Eli Lilly and Company
- Johnson & Johnson Private Limited
- Melinta Therapeutics, LLC
- Vertex Pharmaceuticals Incorporated
- AMP Biotech
- Phoenix Biotechnology Inc.
- Novabiotics
- Other prominent players
Market Segmentation:
The antimicrobial peptides market is categorized on the basis of product , ailments distribution channel, route of administration and end users .Based on product, the antimicrobial peptides market is segmented as plant antimicrobial peptides, bacterial antimicrobial peptides, animal antimicrobial peptides, and insect antimicrobial peptides .Based on Ailments, the market is segmented as pneumonia, hepatitis, bacterial infections, HIV). Based on Distribution Channel, the Antimicrobial Peptides market is segmented as Hospital, Research Institutes, Specialty Clinic, and Pharmacies. Based on route of administration the antimicrobial peptides market is segmented as topical, subcutaneous, intravenous, Based on end users. the antimicrobial peptides market is divided into pharma and healthcare, the agriculture industry, and biological engineering.
Based On End Users, The Pharma And Healthcare Segment Is Accounted As A Major Contributor To The Antimicrobial Peptides Market.
The Pharma and Healthcare category is expected to hold a major share of the global Antimicrobial Peptides Market in 2022. Pharmaceutical firms are becoming more aware of the promise of AMPs as innovative medicinal agents. They may be involved in the research, development, and production of AMP-based drugs to address bacterial infections. These companies may either develop AMPs in-house or collaborate with biotechnology firms specializing in peptide therapeutics. The increasing adoption of AMPs by Pharma and Healthcare as end users reflects the growing recognition of AMPs as valuable tools in the fight against bacterial infections and the need for innovative therapeutic options in the field of antimicrobial therapy.
The Hospitals Segment Witnessed Rapid Growth.
The hospital segment is projected to develop at a rapid rate in the global antimicrobial peptides market. Hospitals are increasingly playing a more prominent role in the distribution of antimicrobial peptides (AMPs). Traditionally, pharmaceutical products, including antimicrobial agents, were primarily distributed through pharmaceutical wholesalers and distributors. However, as the demand for specialized therapeutic products like AMPs grows, hospitals are increasingly becoming direct purchasers and distributors of these products.
In The Region, The North America Antimicrobial Peptides Market Holds A Significant Revenue Share.
The North American Antimicrobial Peptides Market: the market is projected to record a large market revenue share. The anticipated surge in demand for antibiotics within this geographic area, coupled with a rise in research and development endeavors, is projected to propel the industry forward throughout the forecast period. Additionally, the Asia Pacific regional market is poised to witness the most rapid growth, attributable to factors such as the escalating prevalence of diverse infectious diseases, a burgeoning elderly population, and an upsurge in patient awareness regarding their health.
Recent Developments:
- In Jul 2023, Bio Cote Limited and Eco Finish formed a strategic agreement to incorporate Bio Cote technology into antimicrobial surfaces for residential and commercial pools. This partnership delivers antimicrobial additives designed to inhibit the proliferation of bacteria, algae, viruses, and other microbes, enhancing safety and protection for swimmers in pool settings.
- In July 2022, Boehringer Ingelheim, Evotec SE, and biome Rieux collaborated to create a joint venture with the aim of promoting the discovery of innovative antimicrobials to address antimicrobial resistance. This alliance combines the knowledge of both entities to develop creative solutions.
Antimicrobial Peptides Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 223.90 Mn |
|
Revenue Forecast In 2031 |
USD 532.02 Mn |
|
Growth Rate CAGR |
CAGR of 11.65% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Ailments, Route of Administration, Distribution Channel, End User, |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Novozymes A/S, Polypeptide Group, Bachem Holding AG, Wuxi Apptec, Ana Spec Inc. (a Eurofins Company), Merial, Ipsen S.A., AstraZenec, Pfizer Inc, GlaxoSmithKline plc, Merck & Co. Inc., Sandoz International GmbH, Polymedia, Magennis Inc., Probiotic Limited Melinta Therapeutics, LLC, Vertex Pharmaceuticals Incorporated, AMP Biotech, Phoenix Biotechnology Inc., Novabiotics and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
